410 related articles for article (PubMed ID: 19593772)
1. Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues.
Shang X; Wang L; Niu W; Meng G; Fu X; Ni B; Lin Z; Yang Z; Chen X; Wu Y
Eur J Immunol; 2009 Aug; 39(8):2248-58. PubMed ID: 19593772
[TBL] [Abstract][Full Text] [Related]
2. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
3. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
[TBL] [Abstract][Full Text] [Related]
4. Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants.
Ono T; DiLorenzo TP; Wang F; Kalergis AM; Nathenson SG
J Immunol; 1998 Nov; 161(10):5454-63. PubMed ID: 9820521
[TBL] [Abstract][Full Text] [Related]
5. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
6. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures.
Hausmann S; Biddison WE; Smith KJ; Ding YH; Garboczi DN; Utz U; Wiley DC; Wucherpfennig KW
J Immunol; 1999 May; 162(9):5389-97. PubMed ID: 10228016
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
[TBL] [Abstract][Full Text] [Related]
8. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands.
Dressel A; Chin JL; Sette A; Gausling R; Höllsberg P; Hafler DA
J Immunol; 1997 Nov; 159(10):4943-51. PubMed ID: 9366420
[TBL] [Abstract][Full Text] [Related]
9. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
10. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
11. Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL.
Wilson CS; Moser JM; Altman JD; Jensen PE; Lukacher AE
J Immunol; 1999 Apr; 162(7):3933-41. PubMed ID: 10201912
[TBL] [Abstract][Full Text] [Related]
12. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
13. A molecular basis for how a single TCR interfaces multiple ligands.
Boesteanu A; Brehm M; Mylin LM; Christianson GJ; Tevethia SS; Roopenian DC; Joyce S
J Immunol; 1998 Nov; 161(9):4719-27. PubMed ID: 9794402
[TBL] [Abstract][Full Text] [Related]
14. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
15. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
16. Extensive T cell receptor cross-reactivity on structurally diverse haptenated peptides presented by HLA-A2.
Gagnon SJ; Turner RV; Shiue MG; Damirjian M; Biddison WE
Mol Immunol; 2006 Feb; 43(4):346-56. PubMed ID: 16310048
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
18. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.
Rubio-Godoy V; Dutoit V; Rimoldi D; Lienard D; Lejeune F; Speiser D; Guillaume P; Cerottini JC; Romero P; Valmori D
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10302-7. PubMed ID: 11517329
[TBL] [Abstract][Full Text] [Related]
19. Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis.
Kita H; Matsumura S; He XS; Ansari AA; Lian ZX; Van de Water J; Coppel RL; Kaplan MM; Gershwin ME
Hepatology; 2002 Oct; 36(4 Pt 1):918-26. PubMed ID: 12297839
[TBL] [Abstract][Full Text] [Related]
20. Alloreactive and syngeneic CTL are comparably dependent on interaction with MHC class I alpha-helical residues.
Hornell TM; Solheim JC; Myers NB; Gillanders WE; Balendiran GK; Hansen TH; Connolly JM
J Immunol; 1999 Sep; 163(6):3217-25. PubMed ID: 10477590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
